Matchpoint Therapeutics
Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.
Matchpoint Therapeutics is a biotechnology research company. The team counts 32 people. Matchpoint Therapeutics has a website drawing 2K monthly visits and most of the team based in USA.
Employee growth
Matchpoint Therapeutics grew from ~9 employees in June 2021 to 34 by April 2024, reaching 32 by July 2026, tracked weekly in Crustdata's proprietary dataset since June 2021.
Capital raised
Matchpoint Therapeutics has raised $100M across 2 rounds since 2021 - from a $30M Seed Round to a $70M Series A - most recently 1,404 days ago.
-
In October 2022, Matchpoint Therapeutics raised $70M in a Series A round led by Sanofi Ventures, with Vertex Ventures HC, Digitalis Ventures, Atlas Venture, Alexandria Venture Investments, and Access Biotechnology participating.
-
In November 2021, Matchpoint Therapeutics raised $30M in a Seed Round round led by Atlas Venture, with Access Biotechnology participating.
Investors
Matchpoint Therapeutics's 6 backers include leading firms such as Atlas Venture, Sanofi Ventures, Access Biotechnology, and Vertex Ventures HC.
Leadership
Matchpoint Therapeutics's leadership includes Chief Scientific Officer Jared Cumming, President and CEO Andre Turenne, Senior Vice President, Head of Platform and Chemical Biology M. Paola Castaldi, and Senior Vice President, Business Operations Christopher Hren.
Industries & markets
Matchpoint Therapeutics is classified across the following industries, categories, and markets that Crustdata tracks for competitive analysis and sector benchmarking.
See the top Biotechnology Research companies ranked by size, growth and funding.
In the news
Matchpoint Therapeutics has been featured in recent press coverage that Crustdata tracks to surface signals on launches, fundraising, partnerships, and other newsworthy events.
- Novartis, Matchpoint Therapeutics to Co-develop Oral Covalent Inhibitors Under $1 Billion Deal
- Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
- Matchpoint Therapeutics Announces Exclusive Option and License Agreement with Novartis to Develop Oral Inhibitors for Multiple Inflammatory Diseases
- Matchpoint Therapeutics divulges new MK2 inhibitors
Matchpoint Therapeutics Growth Score
Matchpoint Therapeutics has a Crustdata Growth Score of 3 out of 100, which points to modest growth. Behind the number: headcount grew 0% year over year, web traffic grew 3% quarter over quarter, and it last raised funding 47 months ago.
Matchpoint Therapeutics FAQs
Below are 10 of the most common questions about Matchpoint Therapeutics, answered with data tracked and refreshed weekly using Crustdata's proprietary dataset.